Linagliptin as Add on to Basal Insulin in the Elderly
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.
Also called NCT02240680
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 302 participants
- Registry
-
NCT02240680 -
2014-000904-88
-
- Other papers using this trial's data
- Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Colombia, Denmark, Finland, Germany, Greece, Ireland, Japan, Mexico, New Zealand, Poland, Romania, South Africa, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02240680. Randomized; double masking; primary purpose treatment. Start 2014-09-23 (actual); primary completion 2017-04-18 (actual). Results posted on 2018-07-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Linagliptin as Add on to Basal Insulin in the Elderly
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- placebo
- Intervention (Drug)
- linagliptin
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02240680- Content hash
cf32ce841babeafa6d7864a5ce3918a5811afddbd456c3bc5c62b1d719db3ffd